EGFR and non-small cell lung carcinoma: In contrast to first- and second-generation EGFR-TKIs, third-generation EGFR-TKIs, such as osimertinib, have been shown to exhibit enhanced efficacy against NSCLC with the EGFR T790M mutation20,21.